Insulin Resistance Surrogate Indices Calculator
TyG · METS-IR · TyG-BMI · McAuley Index · 2026 cardiometabolic guideline–aligned
ln(TG mg/dL × FBG mg/dL / 2)METS-IR =
ln(2×FBG + TG) × BMI / ln(HDL)TyG-BMI =
TyG × BMI ·
McAuley Index = exp(2.63 − 0.28 × ln(TG mmol/L) − 0.31 × ln(fasting insulin µU/mL))All inputs auto-converted to mg/dL internally. McAuley requires fasting insulin.
| Index | Optimal cut-off | Elevated risk | Primary endpoint |
|---|---|---|---|
| TyG Index | ≥ 8.62 | ≥ 9.0 | MetS, T2DM, MACE prediction |
| METS-IR | ≥ 40 | ≥ 50 | Insulin resistance, CVD risk |
| TyG-BMI | ≥ 210 (M) / ≥ 200 (F) | ≥ 240 | Visceral IR, NAFLD/MASLD |
| TyG-WC | ≥ 800 (M) / ≥ 760 (F) | — | Visceral adiposity, MetS |
| McAuley Index | < 6.0 = IR | < 5.0 | Insulin sensitivity proxy |
TyG = ln(TG × FBG / 2) · METS-IR = ln(2×FBG + TG) × BMI / ln(HDL) · All units auto-converted · No patient data stored or transmitted
- 1.Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as a surrogate for insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299–304. doi:10.1089/met.2008.0034 (Original TyG paper)
- 2.Bello-Chavolla OY, Almeda-Valdes P, Gomez-Velasco D, et al. METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and is associated with metabolic syndrome independently of insulin resistance. Eur J Endocrinol. 2018;178(5):533–544.
- 3.McAuley KA, Williams SM, Mann JI, et al. Diagnosing insulin resistance in the general population. Diabetes Care. 2001;24(3):460–464. (McAuley Index original derivation)
- 4.Er L-K, Wu S, Chou H-H, et al. Triglyceride glucose-body mass index is a simple and clinically useful surrogate marker for insulin resistance in nondiabetic individuals. PLoS ONE. 2016;11(3):e0149731. (TyG-BMI validation)
- 5.Mirr M, Skrypnik D, Bogdanski P, Owecki M. Newly proposed insulin resistance indices METS-IR and TyG-BMI seem not to be better than their predecessors TyG and HOMA-IR in predicting metabolic syndrome in humans. J Endocrinol Invest. 2022;45(4):805–817.
- 6.Zhao Q, Zhang T-Y, Cheng Y-J, et al. Impacts of triglyceride-glucose index on incident coronary heart disease: a prospective cohort study with 136,867 participants. Cardiovasc Diabetol. 2021;20:224. doi:10.1186/s12933-021-01409-0
- 7.Pan K, Nelson LA, Bhatt DL, et al. TyG-derived indices and cardiovascular outcomes: meta-analysis (2024). Eur Heart J Open. 2024;4(2):oeae015.
- 8.American Diabetes Association. Standards of Medical Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1):S1–S321. (Insulin resistance assessment framework)
- 9.Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the Metabolic Syndrome. Circulation. 2009;120(16):1640–1645. (Joint IDF/AHA/NHLBI statement — reference for MetS cut-offs)
For educational and professional reference only. This Insulin Resistance Surrogate Indices Calculator is intended to assist qualified clinicians — endocrinologists, cardiometabolic physicians, diabetes specialists, and allied health professionals. It does not constitute medical advice, diagnosis, or a treatment protocol.
The TyG index, METS-IR, TyG-BMI, TyG-WC, and McAuley Index are epidemiological surrogate markers — not direct measures of insulin resistance. Gold-standard assessment requires the hyperinsulinaemic-euglycaemic clamp, with HOMA-IR as the most widely used validated proxy in routine clinical practice. Surrogates are validated for population screening and risk stratification but have known limitations in individual-level clinical decision-making.
Cut-off values displayed are derived from published validation cohorts and represent population-level thresholds that vary by ethnicity, sex, age, and metabolic phenotype. Asian populations generally demonstrate insulin resistance at lower BMI and TyG thresholds than Western reference populations. Always apply results in the context of the full clinical picture.
The McAuley Index requires fasting insulin, which suffers from poor inter-assay standardisation internationally. HOMA-IR (fasting insulin µU/mL × fasting glucose mmol/L / 22.5) may be more reproducible in laboratories with validated insulin assays. Neither index replaces direct measurement in research settings.
This tool does not store, transmit, or process any patient-identifiable information. All calculations run locally in the user's browser. No liability is assumed for clinical decisions based on these indices.
Last reviewed: January 2026 · ADA Standards 2024 · TyG/METS-IR 2024 meta-analysis · IDF/AHA MetS harmonisation statement
